Medpace Holdings, Inc. with ticker code (MEDP) now have 4 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $302.00 and $281.00 with the average target price sitting at $291.75. Given that the stocks previous close was at $276.81 and the analysts are correct then there would likely be a percentage uptick in value of 5.4%. Also worth taking note is the 50 day moving average now sits at $258.82 while the 200 day moving average is $232.22. The market capitalization for the company is 8.54B. The stock price for the company is currently $278.36 USD
The potential market cap would be $9,002,007,762 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 32.67, revenue per share of $57.77 and a 14.47% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
